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Ochratoxin A (OTA) is a potential inducer of a tubular-interstitial nephropathy in humans and
animals. In our study we addressed the question of involvement of apoptosis in the develop-
ment of OTA-provoked nephrotoxicity. LLC-PK1 kidney cells were treated with nanomolar
and micromolar concentrations of OTA for different lengths of time. The apoptotic process was
estimated by morphological (haematoxylin/eosin staining, fluorescent staining of DNA free
ends – TUNEL assay) and biochemical (MAPKs and Hsps) changes of cells. Forty-eight hours
of treatment with 5  10–6 M OTA significantly decreased cell viability and induced apoptosis
in 30.7 % of cells. In addition, a transient activation of ERK was observed as well as a strong
and prolonged activation of stress kinases, JNK and p38 MAPK, after 12 and 48 hours of treat-
ment. Expression of Hsp72 and Hsp27 was not affected by OTA. The results suggest that
apoptosis mediated by activation of JNK and p38 MAPK might play an important role in
OTA-induced nephrotoxicity in LLC-PK1 cells.
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INTRODUCTION
Ochratoxin A (OTA) is produced as a secondary fungal
metabolite of some Aspergillus and Penicillium strains
and is a frequent contaminant of feed and foodstuffs.1,2
OTA is hazardous to humans and animals because of its
nephrotoxic, hepatotoxic, immunosuppressive, teratoge-
nic, and carcinogenic effects.3–8 Kidneys are the main
target of OTA.9 OTA is known to affect multiple sites of
the nephron: acute exposure mainly affects the proximal
parts, while chronic exposure leads predominantly to da-
mage of the proximal tubule.2 Epidemiological studies
implicate OTA with endemic nephropathy (EN), a pro-
gressive renal fibrosis, and tumours of the urinary
tract.10,11 It has been shown in animals that OTA induces
a tubular-interstitial nephropathy similar to EN as well
as renal adenoma and carcinoma.12,13
Some aspects of OTA toxicity have been attributed
to the phenylalanine moiety responsible for the inhibiti-
on of protein synthesis by competitive inhibition of phe-
nylalanil-tRNA synthase. The open lactone moiety of OTA
molecule is structurally analogous to active sites of some
mitochondrial enzymes, thus OTA may interfere with
oxidative processes such as reactive oxygen species (ROS)
formation and lipid peroxidation (LPO).14–16 OTA toxic-
ity has been also related to the impairment of intracel-
lular calcium handling, competitive inhibition of trans-
port carrier proteins located in the inner mitochondrial
membrane (ATPase, succinate dehydrogenase, and cyto-
chrome c oxidase), inhibition of incorporation of orotic
acid into the RNA, and interference with signal trans-
duction in some cell types.10,16,17
Therefore, exposure to OTA can cause cell deregula-
tion and death: either through overproduction of ROS
and LPO, and disruption of the Ca2+ transport, or through
inhibition of protein synthesis and inhibition of phenyl-
alanine metabolism leading to the reduction of phospho-
enolpyruvate carboxykinase and gluconeogenesis, ulti-
mately inducing severe cell disturbances.18–21
Cells typically die either by apoptosis or necrosis.22
Although the two types of cell death can be differenti-
ated biochemically and morphologically, these processes
are more similar than previously thought.23 In necrosis
the cell membrane loses its integrity and the cell content
is released causing an inflammatory response, while in
apoptosis the cell content remains »well-packed« in the
apoptotic bodies and no inflammation occurs. However,
both types of cell death can be induced by the same pa-
thophysiological signals, can be prevented by anti-apop-
totic mechanisms, and once initiated can switch to the
other type of cell death.23
OTA has been reported to activate apoptotic responses
in several cell types, including Hak, HeLa cells, MDCK-
C7, MDCK-C11, OK, and NRK-49F fibroblasts.24–26
Apoptosis of liver and kidney cells has been observed
after OTA administration to mice and rats in vivo.27,28 In-
duction of apoptosis via the JNK pathway has been sug-
gested for some OTA-induced changes in the renal func-
tion as well as for part of its teratogenic action.9,29 The
carcinogenic potential of OTA has been also correlated
with its capacity to induce apoptosis and affect cell sig-
nalling in gap junctional communication-proficient rat
liver and human kidney epithelial cells grown in vitro.10
However, the exact molecular mechanisms involved in
the induction of apoptosis by OTA have not yet been
fully clarified.
In this study, the molecular mechanism of OTA tox-
icity was investigated in the LLC-PK1 epithelial kidney
cells. The ability of different OTA concentrations to in-
duce apoptotic signals was estimated by biochemical
and morphological changes in LLC-PK1 cells.
EXPERIMENTAL
Cell Culture
A pig kidney cell line corresponding to the proximal epithe-
lial cells, LLC-PK1, was cultured at 37 C in a 5 % CO2 at-
mosphere in MEM culture medium supplemented with 10 %
heat-inactivated foetal bovine serum (FBS), 100 IU/ml
( 60 g/ml) penicillin, 100 g/ml streptomycin, 2.5 g/ml
amphotericin B, 290 g/ml L-glutamine and 2.5 mg/ml so-
dium hydrogen carbonate. Cells were plated in 6 well plat-
es, usually at a plating density of 1–3 x 106 cells/ml.
Cells were harvested by removing the medium, wash-
ing in phosphate-buffered saline (PBS; 20 mmol dm–3 phos-
phate buffer, 150 mmol dm–3 NaCl, pH = 7.2), treating with
trypsin (0.25 % solution in PBS) for 5 min, and centrifug-
ing at 600 g at 4 °C for 5 min.
Treatment
LLC-PK1 cells were treated with 0.10, 0.25, 0.50, 1.00, and
5.00 x 10–6 M OTA for 2, 4, 6, 12, 24 or 48 hours. OTAwas
dissolved in ethanol at a concentration of 5 x 10–6 M, and
the final concentration was obtained by appropriate dilution
in the culture medium. The final ethanol concentration in
the medium was 0.025 %. Ethanol was added to the control
cells in a final concentration of 0.025 %.
Trypan Blue Exclusion Assay
To assess cell viability, 0.5 ml of 0.4 % Trypan blue solu-
tion was added to the test tube. 0.3 ml PBS was added to
0.2 ml cell suspension, the suspension was mixed and then
incubated for 10 min. Non-viable cells (dye-stained) as well
as viable cells (unstained) were counted under light micro-
scopy.
Whole Cell Lysis
Treated and untreated LLC-PK1 cells were washed twice
with cold PBS and lysed with 100 L of ice-cold whole-
cell lysis buffer (50 mmol dm–3 Tris-HCl pH = 8.0, 137
mmol dm–3 NaCl, 1 % Nonident P-40, 10 % glycerol, and a
»Complete protease inhibitor« cocktail tablet). After 20 mi-
nutes, cell lysates were centrifuged at 4 C at 14000 rpm.
Samples were denatured by boiling for 3 minutes with 6 
Laemmli sample buffer (0.375 M Tris-HCl pH = 6.8, 12 g/100
ml SDS, 3 % glycerol, 0.2 g/100 ml bromophenol blue, 12 %
-mercaptoethanol in distilled water).
Haematoxylin/Eosin Staining of Cells
In order to visualize and estimate apoptotic cells, LLC-PK1
cells were stained with haematoxylin/eosin following OTA
treatment. For this purpose, LLC-PK1 cells were cultured
on coverslips in small Petri dishes. Confluent cells were
treated with OTA as described in Treatment. After removal
of culture medium, cells were stained with haematoxylin
and eosin using Kiernan’s method.30
Fluorescent Staining of DNA Fragments (TUNEL
Assay)
Terminal deoxyribonucleotidyl transferase (TDT)-mediated
dUTP-digoxigenin nick end labelling of DNA (TUNEL as-
say) was used for visualizing and estimating apoptotic cells.
The assay was carried out using dUTP-fluorescein isothio-
cyanate (FITC) according to the manufacturer’s instructions
(In Situ Cell Death Detection Kit, Boehringer Mannheim,
Germany).
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Western Blotting
Western blot analysis was performed in order to assess
ERK1/2, JNK 1/2, p38, Hsp27 and Hsp72 protein expres-
sion as well as ERK1/2, JNK 1/2 and p38 activation (phos-
phorylation).
35 g of total proteins was loaded for each sample onto
a 12 % polyacrylamide gel usually run at 100 V. Transfer
onto nitrocellulose membrane was conducted at 250 mA for
90 minutes. Membranes were blocked for one hour with
blocking buffer containing 4 g BSA in 100 ml of TBS+T
(25 mmol dm–3 Tris pH = 7.6, 150 mmol dm–3 NaCl, 0.05 %
Tween 20). Membranes were probed overnight at room
temperature with either anti-JNK-P antibody (Promega) di-
luted 1:5000 in blocking buffer, anti-ERK-P antibody (Pro-
mega) diluted 1:5000 in blocking buffer, anti-p38-P antibody
(Promega) diluted 1:2000 in blocking buffer, anti-JNK1(FL)
antibody (Santa Cruz Biotechnology) diluted 1:800 in block-
ing buffer, anti-ERK1(C-16) antibody (Santa Cruz Biotech-
nology) diluted 1:1000 in blocking buffer, anti-p38(C-20)
antibody (Santa Cruz Biotechnology) diluted 1:1000 in
blocking buffer, anti-Hsp27 antibody (Stressgene) diluted
1:5000 in blocking buffer, anti-Hsp72 antibody (Stressge-
ne) diluted 1:1000 in blocking buffer or anti-actin antibody
(Sigma) diluted 1:1000 in blocking buffer. A horseradish
peroxidase-conjugated secondary antibody (Amersham Bio-
sciences) diluted 1:4000 in the solution of 4 g BSA in 100
ml of TBS+T was used to allow detection of the appropri-
ate bands using an enhanced chemiluminescence reagent
and film. All experiments were repeated at least three times
and representative blots were analyzed using the ScionIma-
ge software for Windows (Scion Corporation).
Statistical Analysis
Data from this study were analyzed by a one-way analysis
of variance (ANOVA) followed by a multiple comparison
procedure (Dunnett’s test). The level of P<0.05 was consid-
ered statistically significant for all the tests performed. We
also performed Levene’s test and established homogeneity
of variance among all the groups of data assessed. The
SPSS computer program for MS Windows, release 6.0, was
used for statistical analysis.
RESULTS AND DISCUSSION
Time- and Dose-dependent Viability of LLC-PK1
Cells Treated with OTA
The fungal metabolite OTA has been shown to exert
chronic damaging effects in mammals at low concentra-
tions.2,31 Chronic exposure to OTA leads to impairment
of renal function and morphology as well as to increased
incidence of renal adenoma and carcinoma. The mecha-
nism of action of low OTA concentrations (<1 mol
dm–3 for most cultured kidney epithelial cell lines) has
not yet been unveiled satisfactorily. It seems that the dis-
ruption of cell viability by necrosis is associated with
impaired protein synthesis and/or ROS generation caused
by higher OTA concentrations (>1 mol dm–3 for most
cultured kidney epithelial cell lines).29,31,32 It has been
reported that OTA affects multiple sites of the nephron;
acute exposure mainly affects the proximal parts, while
chronic exposure affects predominantly proximal tubules.
LLC-PK1 cells are therefore widely used as the in vitro
model of cultured tubular epithelial cells, since they re-
tain several characteristics of the proximal tubule cells.2,33
To investigate whether OTA impairs cell viability,
we incubated LLC-PK1 cells with different OTA con-
centrations for 12, 24, and 48 hours. As shown in Figure 1,
5 mol dm–3 OTA significantly decreased viability of
LLC-PK1 cells after 12 (by 50 %), 24 (by 76 %), and 48
(by 84 %) hours of treatment, while 1 mol dm–3 OTA
significantly decreased cell viability only after 24 (by
45 %) and 48 (by 67 %) hours of treatment. Lower OTA
concentrations (100–500 nmol dm–3) affected signifi-
cantly the viability of LLC-PK1 cells only if the cells
were treated with OTA for 48 hours.
We addressed the question whether the observed de-
crease in viability of LLC-PK1 cells reflects necrotic or
apoptotic cell death. We therefore estimated the morpho-
logy of adherent LLC-PK1 cells exposed to the same OTA
treatment by haematoxylin/eosin staining and TUNEL
assay. Our results demonstrate that both low (250–500
nmol dm–3) and high (1–5 mol dm–3) OTA concentra-
tions significantly increased the number of LLC-PK1
cells undergoing apoptosis after 24 and 48 hours of
treatment, as summarized in Figure 2.
Activation of MAPKs by OTA
Schramek et al. have shown that OTA has the ability
to activate members of the mitogen-activated protein ki-
nase (MAPK) family.29 MAPKs are important participants
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Figure 1. Effects of OTA on LLC-PK1 cell viability. Cells were treat-
ed with OTA in a concentration range from 100 nmol dm–3 to 5
mol dm–3. Cell viability was examined after 12, 24 and 48 hours
by the Trypan blue exclusion assay. Values for untreated control
cells were taken as 100 % and values for OTA-treated cells were
taken as the decrease of the number of viable (unstained) cells ex-
pressed in percents. Data represent the mean + SD of three repli-
cates for each experimental condition. Significantly different from
control values, P<0.05; significantly different from control and
itself, *P<0.05.
in the intracellular signalling pathways that transduce
signals from the plasma membrane into the nucleus,
thereby influencing various cellular responses such as cell
growth and transformation, as well as differentiation and
invasion.34–36 There are four major classes of MAPKs, in-
cluding extracellular signal-regulated kinase 1/2 (ERK1/2),
c-Jun N-terminal kinase/stress-activated protein kinase
(JNK/SAPK), p38 MAPK, and big MAPK (BMK)/ERK5.
MAPKs are activated by phosphorylation of both threo-
nine and the neighbouring tyrosine regulatory site by a
specific upstream protein kinase.37
Upon activation, MAPKs phosphorylate other cyto-
plasmatic proteins and translocate from the cytoplasm to
the nucleus to regulate the activity of transcription fac-
tors, thus modulating the expression of different genes.
It is known that many mitogens and growth factors
activate ERK1/2 pathways to evoke cell survival and
proliferation.38,39 However, stress kinases, JNK and p38
MAPK, are involved in the transduction of pathological
signals and respond to proinflammatory and stressful
physical or chemical stimuli.40,41 JNK activation has been
shown to be associated with apoptosis in some cell types
by induction of AP-1-dependent gene expression.42–44
On the other hand, p38 MAPK is necessary for stress-in-
duced expression of proinflammatory cytokines and growth
factors.45,46 The role of p38 MAPK in terms of cell
death was mostly considered to be sensitizing to or en-
hancing apoptosis.47 It has been reported that OTA in-
duces JNK activation and apoptosis in MDCK-C7 cells,
another well established renal epithelial cell line.9 To in-
vestigate whether OTA affects MAPKs activation in LLC-
PK1 cells, we monitored the expression and activation
of ERK1/2, JNK1/2 and p38 MAPK after 2, 4, 6, 12 and
24 hours of treatment. Summarized results of these ex-
periments are shown in Figure 3. Two hours of OTA
treatment caused activation of ERK1/2 in a dose-depend-
ent manner (Figure 3a). This activation was transient; 4-
and 6-hour OTA treatments did not activate ERK1/2 (data
not shown). However, we observed strong activation of
JNK and p38 upon 6 (Figure 3b; we got the same ex-
pression pattern after 6 and 12 hours of treatment), 12
(Figure 3b) and 24 hours (Figure 3c) of OTA treatment.
It is known that a dynamic balance between the anti-
apoptotic ERK pathway and the pro-apoptotic JNK/p38
MAPK pathways is important for determining whether a
cell survives or undergoes apoptosis.48 Our results sug-
gest that this balance was disrupted. Pro-apoptotic JNK/p38
MAPK signals directed cells towards programmed cell
death while a transient activation of ERK1/2 pathway
was not strong enough to stimulate cell survival.
Expression of Hsp72 and Hsp27 Is
not Affected by OTA
Highly conserved heat shock proteins (Hsps) accumulate
in cells responding to heat and to a variety of other stress-
ful stimuli. Hsps, which function mainly as molecular
chaperones, allow the cells to adapt to changes in their
environment and to survive under lethal conditions. There
is interplay between the molecules taking part in cell
stress and cell death responses, and Hsps appear to func-
tion at key regulatory points in the control of apoptotic
process. Hsp72 (inducible member of the Hsp70 family)
and Hsp27 (member of the small Hsps family) are known
as regulators of the intrinsic pathway of apoptosis oper-
ating at several control points, including inhibition of
apoptosis inducing factor (AIF), inhibition of apoptoso-
me formation and thereby prevention of caspase-9 matu-
ration, and inhibition of caspase-3.49–53 In addition, Hsp70
and Hsp27 modulate the extrinsic pathway of apoptosis
by inhibiting the Daxx pathway and JNK activation.54,55
We have previously reported that the expression of Hsp70
family members, Hsp72 and Hsc73, in LLC-PK1 and
MDCK cells as well as in rat kidney tissue is not affect-
ed by OTA treatment.56 In this study, we monitored the
expression of Hsp72 and Hsp27 in LLC-PK1 cells ex-
posed to high and low OTA concentrations for different
periods of time. As shown in Figure 4, OTA did not af-
fect the expression either of Hsp72 or Hsp27. Hsp genes
are regulated at the transcriptional level by the heat shock
factor (HSF), which binds to the heat shock promoter el-
ement (HSE).57,58 Under stressful conditions, HSF1 is
hyperphosphorylated on multiple serine residues in a
ras-dependent manner by the MAPK family members
and the resulting phosphorylated trimers have a capacity
to bind DNA and translocate from the cytoplasm to the
nucleus.59 Under normal growth conditions, HSF1 activ-
ity is repressed and exists in an inert monomeric state
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Figure 2. Apoptosis induction by OTA. LLC-PK1 cells were treated
with OTA in a concentration range between 100 nmol dm–3 and
5 mol dm–3 for 24 and 48 hours. Cells were stained with hae-
matoxylin/eosin and TUNEL assay, and quantification of apoptotic cells
was performed. Data represent the mean + SD of six replicates for
each experimental condition. Significantly different from control values,
*P<0.05.
characterized by constitutive phosphorylation on critical
serine residues located in the regulatory domain.60 JNK
has been reported to be the MAPK kinase in mammals
that binds HSF-1 in its conserved domain and phospho-
rylates HSF-1 within its regulatory domain. Phosphory-
lation of HSF-1 by JNK leads to suppression of its trans-
criptional activity by rapidly clearing HSF1 from sites of
transcription.61,62
We suggest that OTA-induced JNK activation pre-
vented hsp genes overexpression in LLC-PK1 cells by a
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Figure 3. OTA provokes activation of MAPKs. LLC-PK1 cells were exposed to OTA in a concentration range from 100 nmol dm–3 to 5
mol dm–3 for 2 (a), 6 and 12 (b), and 24 (c) hours. Western blot analysis was performed as described in Experimental. Representative
blots for expression and activation of ERK, JNK and p38 MAPK are shown. Data represents the mean + SD of relative intensity of MAPKs
activation.
similar mechanism. Thus, Hsp72 and Hsp27 could not
exert their protective function which, together with stress
kinases activation, contributed to the induction of apop-
tosis in LLC-PK1 cells by OTA.
CONCLUSIONS
In this study, we have examined the effects of OTA on
survival of LLC-PK1 cells, cultured kidney epithelial
cells that have retained several characteristics of the pro-
ximal tubule cells.
The fungal metabolite OTA has been shown to exert
chronic damaging effects in mammals at low concentra-
tions. It seems that the disruption of cell viability by ne-
crosis is associated with impaired protein synthesis and/or
ROS generation caused by higher OTA concentrations
(>1 mol dm–3 for most cultured kidney epithelial cell
lines). The mechanism of action of low OTA concentra-
tions has not yet been unveiled satisfactorily. However,
apoptosis has been suggested to be an important event in
OTA-provoked cytotoxicity.
In our study, LLC-PK1 cells were treated with high
and low OTA concentrations (from 100 nmol dm–3 to 5
mol dm–3) for different periods of time, and we found
that the observed decrease in cell viability was associ-
ated with an increased number of apoptotic cells. Apop-
tosis, estimated by morphological and biochemical chan-
ges in LLC-PK1 cells, was mediated by strong and pro-
longed activation of JNK and p38 MAPK. In contrast,
the activation of anti-apoptotic MAPK, ERK1/2, was
transient. Moreover, the level of expression of Hsp72 and
Hsp27, important inhibitors of the apoptotic process,
was not affected by OTA. Therefore, we suggest that the
signals transduced by those protective molecules were
not strong enough to shift the anti-apoptotic/pro-apopto-
tic balance within LLC-PK1 cells towards cell survival.
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SA@ETAK
Okratoksin A izaziva apoptozu u LLC-PK1 stanicama aktiviraju}i JNK i p38 MAPK
Karmela Bari{i}, Lada Rumora, József Petrik, Ivana ^epelak i Tihana @ani}-Grubi{i}
Okratoksin A (OTA) mo`e izazvati tubularno-intersticijsku nefropatiju u ljudi i `ivotinja. Cilj na{eg istra-
`ivanja bio je ispitati ulogu apoptoze u nastanku nefrotoksi~nosti koju uzrokuje OTA. Na{ eksperimentalni mo-
del bile su LLC-PK1 bubre`ne stanice izlo`ene djelovanju OTA, od nanomolarnih do mikromolarnih koncen-
tracija kroz razli~ita vremenska razdoblja. Apoptoza je u stanicama utvr|ena na temelju morfolo{kih (bojanje
stanica hematoksilin/eozinom, fluorescentno bojanje slobodnih krajeva DNA tzv. TUNEL) i biokemijskih (MAP
kinaze, Hsps) promjena. 48-satno izlaganje stanica 5 x 10–6 M OTA zna~ajno je smanjilo stani~nu vijabilnost i
potaknulo apoptozu u 30,7 % stanica. Osim toga, utvr|ena je kratkotrajna aktivacija ERK te sna`na i dugo-
trajna aktivacija JNK i p38 MAPK nakon 6-, 12- i 48-satnoga tretiranja. OTA nije utjecao na razinu Hsp72 i
Hsp27. Rezultati istra`ivanja ukazuju da je apoptoza posredovana aktivacijom JNK i p38 MAPK va`an doga|aj
u razvoju nefrotoksi~nosti izazvanoj djelovanjem OTA na LLC-PK1 stanice.
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